Identification

Name
Disopyramide
Accession Number
DB00280  (APRD00507)
Type
Small Molecule
Groups
Approved
Description

A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.

Structure
Thumb
Synonyms
  • Disopiramida
  • Disopyramidum
Product Ingredients
IngredientUNIICASInChI Key
Disopyramide phosphateN6BOM1935W22059-60-5CGDDQFMPGMYYQP-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NorpaceCapsule, gelatin coated100 mg/1OralCarilion Materials Management1982-07-20Not applicableUs
NorpaceCapsule, gelatin coated150 mg/1OralCarilion Materials Management1982-07-20Not applicableUs
NorpaceCapsule, gelatin coated100 mg/1OralG.D. Searle LLC Division of Pfizer Inc1977-09-01Not applicableUs
NorpaceCapsule, gelatin coated150 mg/1OralG.D. Searle LLC Division of Pfizer Inc1977-09-01Not applicableUs
Norpace Cap 100mgCapsule100 mgOralRoberts Pharmaceutical1994-12-311999-08-11Canada
Norpace Cap 150mgCapsule150 mgOralRoberts Pharmaceutical1994-12-311999-08-11Canada
Norpace CRCapsule, extended release150 mg/1OralG.D. Searle LLC Division of Pfizer Inc1982-07-20Not applicableUs
Norpace CRCapsule, extended release100 mg/1OralG.D. Searle LLC Division of Pfizer Inc1982-07-20Not applicableUs
Norpace CR 150mgTablet, extended release150 mgOralShire Biochem Inc1994-12-312004-04-30Canada
RythmodanCapsule150 mgOralSanofi Aventis2003-09-152012-05-24Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Disopyramide PhosphateCapsule100 mg/1OralActavis Pharma Company1985-05-31Not applicableUs
Disopyramide PhosphateCapsule100 mg/1OralAv Kare, Inc.2014-01-03Not applicableUs
Disopyramide PhosphateCapsule100 mg/1OralMayne Pharma2016-08-03Not applicableUs
Disopyramide PhosphateCapsule100 mg/1OralTeva1990-09-30Not applicableUs00093 3127 01 nlmimage10 c12de08f
Disopyramide PhosphateCapsule150 mg/1OralAv Kare, Inc.2014-01-03Not applicableUs
Disopyramide PhosphateCapsule150 mg/1OralActavis Pharma Company1985-05-31Not applicableUs
Disopyramide PhosphateCapsule150 mg/1OralMayne Pharma2016-08-03Not applicableUs
Disopyramide PhosphateCapsule150 mg/1OralTeva1990-09-30Not applicableUs00093 3129 01 nlmimage10 b32dd9fe
Disopyramide PhosphateCapsule100 mg/1OralCarilion Materials Management1990-09-30Not applicableUs
Disopyramide PhosphateCapsule150 mg/1OralCarilion Materials Management1990-09-30Not applicableUs
International/Other Brands
Dicorantil (Sanofi) / Isorythm (SERP) / Lispine (Sawai Seiyaku) / Ritmodan (Sanofi)
Categories
UNII
GFO928U8MQ
CAS number
3737-09-5
Weight
Average: 339.4745
Monoisotopic: 339.231062565
Chemical Formula
C21H29N3O
InChI Key
UVTNFZQICZKOEM-UHFFFAOYSA-N
InChI
InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)
IUPAC Name
4-[bis(propan-2-yl)amino]-2-phenyl-2-(pyridin-2-yl)butanamide
SMILES
CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C1=NC=CC=C1)C(C)C

Pharmacology

Indication

For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, ventricular pre-excitation and cardiac dysrhythmias. It is a Class Ia antiarrhythmic drug.

Structured Indications
Pharmacodynamics

Disopyramide is an antiarrhythmic drug indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia that are life-threatening. In man, Disopyramide at therapeutic plasma levels shortens the sinus node recovery time, lengthens the effective refractory period of the atrium, and has a minimal effect on the effective refractory period of the AV node. Little effect has been shown on AV-nodal and His-Purkinje conduction times or QRS duration. However, prolongation of conduction in accessory pathways occurs.

Mechanism of action

Disopyramide is a Type 1A antiarrhythmic drug (ie, similar to procainamide and quinidine). It inhibits the fast sodium channels. In animal studies Disopyramide decreases the rate of diastolic depolarization (phase 4) in cells with augmented automaticity, decreases the upstroke velocity (phase 0) and increases the action potential duration of normal cardiac cells, decreases the disparity in refractoriness between infarcted and adjacent normally perfused myocardium, and has no effect on alpha- or beta-adrenergic receptors.

TargetActionsOrganism
ASodium channel protein type 5 subunit alpha
inhibitor
Human
UMuscarinic acetylcholine receptor M1
antagonist
Human
UMuscarinic acetylcholine receptor M2
antagonist
Human
UMuscarinic acetylcholine receptor M3
antagonist
Human
UPotassium voltage-gated channel subfamily D member 2
inhibitor
Human
UPotassium voltage-gated channel subfamily D member 3
inhibitor
Human
UPotassium voltage-gated channel subfamily H member 2
inhibitor
Human
UAlpha-1-acid glycoprotein 2Not AvailableHuman
Absorption

Nearly complete

Volume of distribution
Not Available
Protein binding

50%-65%

Metabolism

Hepatic

Route of elimination

In healthy men, about 50% of a given dose of disopyramide is excreted in the urine as the unchanged drug, about 20% as the mono-N-dealkylated metabolite and 10% as the other metabolites.

Half life

6.7 hours (range 4-10 hours)

Clearance
Not Available
Toxicity

LD50=580 mg/kg in rats

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Disopyramide Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedione2,4-thiazolidinedione may increase the hypoglycemic activities of Disopyramide.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Disopyramide.Experimental
AcarboseAcarbose may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
AcebutololDisopyramide may increase the bradycardic activities of Acebutolol.Approved
AcetohexamideAcetohexamide may increase the hypoglycemic activities of Disopyramide.Investigational, Withdrawn
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Disopyramide.Approved, Vet Approved
AICA ribonucleotideAICA ribonucleotide may increase the hypoglycemic activities of Disopyramide.Experimental, Investigational
AlaproclateAlaproclate may increase the hypoglycemic activities of Disopyramide.Experimental
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
AllicinAllicin may increase the hypoglycemic activities of Disopyramide.Investigational
AlogliptinAlogliptin may increase the hypoglycemic activities of Disopyramide.Approved
AloxiprinAloxiprin may increase the hypoglycemic activities of Disopyramide.Experimental
AlprenololDisopyramide may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AmantadineAmantadine may increase the QTc-prolonging activities of Disopyramide.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Disopyramide.Approved
AmiodaroneAmiodarone may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Disopyramide.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Disopyramide.Approved
AnagrelideAnagrelide may increase the QTc-prolonging activities of Disopyramide.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
AprepitantThe serum concentration of Disopyramide can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
ArotinololDisopyramide may increase the bradycardic activities of Arotinolol.Approved, Investigational
Arsenic trioxideDisopyramide may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherDisopyramide may increase the QTc-prolonging activities of Artemether.Approved
AsenapineDisopyramide may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe metabolism of Disopyramide can be decreased when combined with Atazanavir.Approved, Investigational
AtenololDisopyramide may increase the bradycardic activities of Atenolol.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Disopyramide.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Disopyramide.Approved
BalaglitazoneBalaglitazone may increase the hypoglycemic activities of Disopyramide.Investigational
BalsalazideBalsalazide may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
BedaquilineBedaquiline may increase the QTc-prolonging activities of Disopyramide.Approved
BefunololDisopyramide may increase the bradycardic activities of Befunolol.Experimental
Bempedoic acidBempedoic acid may increase the hypoglycemic activities of Disopyramide.Investigational
BenmoxinBenmoxin may increase the hypoglycemic activities of Disopyramide.Withdrawn
BetaxololDisopyramide may increase the bradycardic activities of Betaxolol.Approved
BevantololDisopyramide may increase the bradycardic activities of Bevantolol.Approved
BisoprololDisopyramide may increase the bradycardic activities of Bisoprolol.Approved
BoceprevirThe metabolism of Disopyramide can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololDisopyramide may increase the bradycardic activities of Bopindolol.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
BosentanThe serum concentration of Disopyramide can be decreased when it is combined with Bosentan.Approved, Investigational
BrofaromineBrofaromine may increase the hypoglycemic activities of Disopyramide.Experimental
BucindololDisopyramide may increase the bradycardic activities of Bucindolol.Investigational
BuforminBuformin may increase the hypoglycemic activities of Disopyramide.Investigational, Withdrawn
BufuralolDisopyramide may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BupranololDisopyramide may increase the bradycardic activities of Bupranolol.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Disopyramide.Approved
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Disopyramide.Approved
CarbamazepineThe metabolism of Disopyramide can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the hypoglycemic activities of Disopyramide.Experimental, Investigational
CarbomycinCarbomycin may increase the QTc-prolonging activities of Disopyramide.Vet Approved
CarbutamideCarbutamide may increase the hypoglycemic activities of Disopyramide.Experimental
CaroxazoneCaroxazone may increase the hypoglycemic activities of Disopyramide.Withdrawn
CarteololDisopyramide may increase the bradycardic activities of Carteolol.Approved
CarvedilolDisopyramide may increase the bradycardic activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may increase the hypoglycemic activities of Disopyramide.Experimental
CeliprololDisopyramide may increase the bradycardic activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Disopyramide can be increased when it is combined with Ceritinib.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
ChlorpropamideDisopyramide may increase the hypoglycemic activities of Chlorpropamide.Approved
CiglitazoneCiglitazone may increase the hypoglycemic activities of Disopyramide.Experimental
CinoxacinCinoxacin may increase the hypoglycemic activities of Disopyramide.Approved, Investigational, Withdrawn
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
CisaprideDisopyramide may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the hypoglycemic activities of Disopyramide.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Disopyramide.Approved
ClemastineThe metabolism of Disopyramide can be decreased when combined with Clemastine.Approved
ClomipramineClomipramine may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
CloranololDisopyramide may increase the bradycardic activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Disopyramide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Disopyramide.Approved
CobicistatThe metabolism of Disopyramide can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Disopyramide can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Disopyramide can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Disopyramide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Disopyramide can be decreased when it is combined with Dabrafenib.Approved
DapoxetineDapoxetine may increase the hypoglycemic activities of Disopyramide.Investigational
DarunavirThe metabolism of Disopyramide can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Disopyramide can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Disopyramide can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Disopyramide.Approved
DelavirdineThe metabolism of Disopyramide can be decreased when combined with Delavirdine.Approved
DeoxyspergualinDeoxyspergualin may increase the hypoglycemic activities of Disopyramide.Investigational
dersalazinedersalazine may increase the hypoglycemic activities of Disopyramide.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Disopyramide.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Disopyramide.Approved
DesvenlafaxineDesvenlafaxine may increase the hypoglycemic activities of Disopyramide.Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Disopyramide.Approved
DihydroergotamineThe metabolism of Disopyramide can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Disopyramide.Illicit
DiltiazemThe metabolism of Disopyramide can be decreased when combined with Diltiazem.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideDofetilide may increase the QTc-prolonging activities of Disopyramide.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Disopyramide.Approved
DomperidoneDisopyramide may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Disopyramide.Approved
DoxycyclineThe metabolism of Disopyramide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Disopyramide can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
DulaglutideDulaglutide may increase the hypoglycemic activities of Disopyramide.Approved
DuloxetineDuloxetine may increase the hypoglycemic activities of Disopyramide.Approved
EliglustatDisopyramide may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinEmpagliflozin may increase the hypoglycemic activities of Disopyramide.Approved
EnoxacinEnoxacin may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
EnzalutamideThe serum concentration of Disopyramide can be decreased when it is combined with Enzalutamide.Approved
EpanololDisopyramide may increase the bradycardic activities of Epanolol.Experimental
EribulinEribulin may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
EscitalopramEscitalopram may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
EsmololDisopyramide may increase the bradycardic activities of Esmolol.Approved
EtoperidoneEtoperidone may increase the hypoglycemic activities of Disopyramide.Withdrawn
EtravirineThe serum concentration of Disopyramide can be decreased when it is combined with Etravirine.Approved
ExenatideExenatide may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Disopyramide.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Disopyramide.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Disopyramide.Approved
FingolimodFingolimod may increase the arrhythmogenic activities of Disopyramide.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Disopyramide.Approved, Withdrawn
FleroxacinFleroxacin may increase the hypoglycemic activities of Disopyramide.Approved
FluconazoleFluconazole may increase the QTc-prolonging activities of Disopyramide.Approved
FlumequineFlumequine may increase the hypoglycemic activities of Disopyramide.Withdrawn
FluoxetineFluoxetine may increase the hypoglycemic activities of Disopyramide.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Disopyramide.Approved, Illicit
FlupentixolDisopyramide may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluvoxamineThe metabolism of Disopyramide can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
FosamprenavirThe metabolism of Disopyramide can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Disopyramide can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Disopyramide.Approved
FosphenytoinDisopyramide may increase the QTc-prolonging activities of Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypoglycemic activities of Disopyramide.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Disopyramide can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Disopyramide.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Disopyramide.Approved
GarenoxacinGarenoxacin may increase the hypoglycemic activities of Disopyramide.Investigational
GatifloxacinGatifloxacin may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
GemifloxacinGemifloxacin may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
GlibornurideGlibornuride may increase the hypoglycemic activities of Disopyramide.Investigational, Withdrawn
GliclazideDisopyramide may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideGlimepiride may increase the hypoglycemic activities of Disopyramide.Approved
GlipizideDisopyramide may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneGliquidone may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
GLPG-0492GLPG-0492 may increase the hypoglycemic activities of Disopyramide.Investigational
GlyburideDisopyramide may increase the hypoglycemic activities of Glyburide.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Disopyramide.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
GrepafloxacinGrepafloxacin may increase the hypoglycemic activities of Disopyramide.Investigational, Withdrawn
GuacetisalGuacetisal may increase the hypoglycemic activities of Disopyramide.Experimental
GusperimusGusperimus may increase the hypoglycemic activities of Disopyramide.Investigational
HaloperidolHaloperidol may increase the QTc-prolonging activities of Disopyramide.Approved
HarmalineHarmaline may increase the hypoglycemic activities of Disopyramide.Experimental
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the hypoglycemic activities of Disopyramide.Experimental
HistrelinHistrelin may increase the QTc-prolonging activities of Disopyramide.Approved
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Disopyramide.Experimental
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Disopyramide.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
IbutilideDisopyramide may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Disopyramide can be increased when it is combined with Idelalisib.Approved
IloperidoneDisopyramide may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Disopyramide can be decreased when combined with Imatinib.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Disopyramide.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Disopyramide.Approved
IndalpineIndalpine may increase the hypoglycemic activities of Disopyramide.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Disopyramide.Approved
IndenololDisopyramide may increase the bradycardic activities of Indenolol.Withdrawn
IndinavirThe metabolism of Disopyramide can be decreased when combined with Indinavir.Approved
Insulin AspartDisopyramide may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirDisopyramide may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Disopyramide.Approved
Insulin GlulisineDisopyramide may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanInsulin Human may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Disopyramide.Approved
Insulin PorkInsulin Pork may increase the hypoglycemic activities of Disopyramide.Approved
IproclozideIproclozide may increase the hypoglycemic activities of Disopyramide.Withdrawn
IproniazidIproniazid may increase the hypoglycemic activities of Disopyramide.Withdrawn
IsavuconazoniumThe metabolism of Disopyramide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Disopyramide.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Disopyramide.Approved
ItraconazoleThe serum concentration of Disopyramide can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Disopyramide.Approved
IvacaftorThe serum concentration of Disopyramide can be increased when it is combined with Ivacaftor.Approved
JosamycinJosamycin may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
KetoconazoleThe serum concentration of Disopyramide can be increased when it is combined with Ketoconazole.Approved, Investigational
KitasamycinKitasamycin may increase the QTc-prolonging activities of Disopyramide.Experimental
LabetalolDisopyramide may increase the bradycardic activities of Labetalol.Approved
LandiololDisopyramide may increase the bradycardic activities of Landiolol.Investigational
LanreotideDisopyramide may increase the hypoglycemic activities of Lanreotide.Approved
LapatinibLapatinib may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Disopyramide.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
LevobunololDisopyramide may increase the bradycardic activities of Levobunolol.Approved
LevofloxacinLevofloxacin may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Disopyramide.Approved
LidocaineDisopyramide may increase the arrhythmogenic activities of Lidocaine.Approved, Vet Approved
LinagliptinLinagliptin may increase the hypoglycemic activities of Disopyramide.Approved
LiraglutideLiraglutide may increase the hypoglycemic activities of Disopyramide.Approved
LithiumLithium may increase the QTc-prolonging activities of Disopyramide.Approved
LopinavirThe metabolism of Disopyramide can be decreased when combined with Lopinavir.Approved
LovastatinThe metabolism of Disopyramide can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Disopyramide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Disopyramide can be increased when combined with Lumacaftor.Approved
LumefantrineDisopyramide may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneLurasidone may increase the QTc-prolonging activities of Disopyramide.Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Disopyramide.Approved
MebanazineMebanazine may increase the hypoglycemic activities of Disopyramide.Withdrawn
MecaserminDisopyramide may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MefloquineMefloquine may increase the QTc-prolonging activities of Disopyramide.Approved
MepindololDisopyramide may increase the bradycardic activities of Mepindolol.Experimental
MesalazineMesalazine may increase the hypoglycemic activities of Disopyramide.Approved
MesteroloneMesterolone may increase the hypoglycemic activities of Disopyramide.Experimental
MetforminMetformin may increase the hypoglycemic activities of Disopyramide.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Disopyramide.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Disopyramide.Approved
Methylene blueMethylene blue may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Disopyramide.Approved
MetipranololDisopyramide may increase the bradycardic activities of Metipranolol.Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
MetoprololDisopyramide may increase the bradycardic activities of Metoprolol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Disopyramide.Approved
MifepristoneThe serum concentration of Disopyramide can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolMiglitol may increase the hypoglycemic activities of Disopyramide.Approved
MiglustatMiglustat may increase the hypoglycemic activities of Disopyramide.Approved
MilnacipranMilnacipran may increase the hypoglycemic activities of Disopyramide.Approved
MinaprineMinaprine may increase the hypoglycemic activities of Disopyramide.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Disopyramide.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Disopyramide.Approved
MitiglinideMitiglinide may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
MitotaneThe serum concentration of Disopyramide can be decreased when it is combined with Mitotane.Approved
MoclobemideMoclobemide may increase the hypoglycemic activities of Disopyramide.Approved
MoexiprilMoexipril may increase the QTc-prolonging activities of Disopyramide.Approved
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
NadololDisopyramide may increase the bradycardic activities of Nadolol.Approved
Nalidixic AcidNalidixic Acid may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
NandroloneNandrolone may increase the hypoglycemic activities of Disopyramide.Experimental, Investigational
NateglinideDisopyramide may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NefazodoneThe metabolism of Disopyramide can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Disopyramide can be decreased when combined with Nelfinavir.Approved
NemonoxacinNemonoxacin may increase the hypoglycemic activities of Disopyramide.Investigational
NetupitantThe serum concentration of Disopyramide can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Disopyramide can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypoglycemic activities of Disopyramide.Withdrawn
NicardipineNicardipine may increase the QTc-prolonging activities of Disopyramide.Approved
NilotinibThe metabolism of Disopyramide can be decreased when combined with Nilotinib.Approved, Investigational
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Disopyramide.Investigational
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Disopyramide.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Disopyramide.Approved
OctamoxinOctamoxin may increase the hypoglycemic activities of Disopyramide.Withdrawn
OctreotideOctreotide may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Disopyramide.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
OlaparibThe metabolism of Disopyramide can be decreased when combined with Olaparib.Approved
OleandomycinOleandomycin may increase the QTc-prolonging activities of Disopyramide.Vet Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Disopyramide.Approved
OlsalazineOlsalazine may increase the hypoglycemic activities of Disopyramide.Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Disopyramide.Approved
OsimertinibThe serum concentration of Disopyramide can be increased when it is combined with Osimertinib.Approved
OxandroloneOxandrolone may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
Oxolinic acidOxolinic acid may increase the hypoglycemic activities of Disopyramide.Experimental
OxprenololDisopyramide may increase the bradycardic activities of Oxprenolol.Approved
OxymetholoneOxymetholone may increase the hypoglycemic activities of Disopyramide.Approved, Illicit
OxytocinOxytocin may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
PalbociclibThe serum concentration of Disopyramide can be increased when it is combined with Palbociclib.Approved
PaliperidoneDisopyramide may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatPanobinostat may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
PargylinePargyline may increase the hypoglycemic activities of Disopyramide.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Disopyramide.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Disopyramide.Approved
PazufloxacinPazufloxacin may increase the hypoglycemic activities of Disopyramide.Investigational
PefloxacinPefloxacin may increase the hypoglycemic activities of Disopyramide.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Disopyramide.Approved
PenbutololDisopyramide may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentamidineDisopyramide may increase the hypoglycemic activities of Pentamidine.Approved
PentobarbitalThe metabolism of Disopyramide can be increased when combined with Pentobarbital.Approved, Vet Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Disopyramide.Approved
PhenelzinePhenelzine may increase the hypoglycemic activities of Disopyramide.Approved
PhenforminPhenformin may increase the hypoglycemic activities of Disopyramide.Approved, Investigational, Withdrawn
PheniprazinePheniprazine may increase the hypoglycemic activities of Disopyramide.Withdrawn
PhenobarbitalThe serum concentration of Disopyramide can be decreased when it is combined with Phenobarbital.Approved
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Disopyramide.Withdrawn
PhenytoinThe serum concentration of Disopyramide can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideDisopyramide may increase the QTc-prolonging activities of Pimozide.Approved
PindololDisopyramide may increase the bradycardic activities of Pindolol.Approved
PioglitazonePioglitazone may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
Pipemidic acidPipemidic acid may increase the hypoglycemic activities of Disopyramide.Experimental
PirlindolePirlindole may increase the hypoglycemic activities of Disopyramide.Approved
Piromidic acidPiromidic acid may increase the hypoglycemic activities of Disopyramide.Experimental
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Disopyramide.Withdrawn
PosaconazoleThe metabolism of Disopyramide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololDisopyramide may increase the bradycardic activities of Practolol.Approved
PramlintidePramlintide may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
PrimaquinePrimaquine may increase the QTc-prolonging activities of Disopyramide.Approved
PrimidoneThe metabolism of Disopyramide can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideDisopyramide may increase the QTc-prolonging activities of Procainamide.Approved
PromazinePromazine may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Disopyramide.Approved
PropafenonePropafenone may increase the arrhythmogenic activities of Disopyramide.Approved
PropofolPropofol may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational, Vet Approved
PropranololDisopyramide may increase the bradycardic activities of Propranolol.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Disopyramide.Approved
PrulifloxacinPrulifloxacin may increase the hypoglycemic activities of Disopyramide.Investigational
QuetiapineDisopyramide may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineDisopyramide may increase the QTc-prolonging activities of Quinidine.Approved
QuinineDisopyramide may increase the hypoglycemic activities of Quinine.Approved
RanolazineRanolazine may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
RasagilineRasagiline may increase the hypoglycemic activities of Disopyramide.Approved
RepaglinideDisopyramide may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RifabutinThe metabolism of Disopyramide can be increased when combined with Rifabutin.Approved
RifampicinThe serum concentration of Disopyramide can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Disopyramide can be increased when combined with Rifapentine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Disopyramide.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
RitonavirThe metabolism of Disopyramide can be decreased when combined with Ritonavir.Approved, Investigational
RosiglitazoneRosiglitazone may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
RosoxacinRosoxacin may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
RufloxacinRufloxacin may increase the hypoglycemic activities of Disopyramide.Experimental
SafrazineSafrazine may increase the hypoglycemic activities of Disopyramide.Withdrawn
SalbutamolSalbutamol may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Disopyramide.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Disopyramide.Approved
SaquinavirThe metabolism of Disopyramide can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Disopyramide.Approved
SelegilineSelegiline may increase the hypoglycemic activities of Disopyramide.Approved, Investigational, Vet Approved
SertralineSertraline may increase the QTc-prolonging activities of Disopyramide.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
SildenafilThe metabolism of Disopyramide can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Disopyramide can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Disopyramide can be increased when it is combined with Simeprevir.Approved
SitafloxacinSitafloxacin may increase the hypoglycemic activities of Disopyramide.Experimental, Investigational
SitagliptinSitagliptin may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
SolifenacinSolifenacin may increase the QTc-prolonging activities of Disopyramide.Approved
SolithromycinSolithromycin may increase the QTc-prolonging activities of Disopyramide.Investigational
SorafenibSorafenib may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
SotagliflozinSotagliflozin may increase the hypoglycemic activities of Disopyramide.Investigational
SotalolDisopyramide may increase the bradycardic activities of Sotalol.Approved
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
St. John's WortThe serum concentration of Disopyramide can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StanozololStanozolol may increase the hypoglycemic activities of Disopyramide.Approved, Vet Approved
StiripentolThe serum concentration of Disopyramide can be increased when it is combined with Stiripentol.Approved
SulfadiazineDisopyramide may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Disopyramide.Approved
SulfisoxazoleSulfisoxazole may increase the hypoglycemic activities of Disopyramide.Approved, Vet Approved
SulodexideSulodexide may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
TalinololDisopyramide may increase the bradycardic activities of Talinolol.Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Disopyramide.Approved
TelaprevirThe metabolism of Disopyramide can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Disopyramide.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Disopyramide.Approved
TemafloxacinTemafloxacin may increase the hypoglycemic activities of Disopyramide.Withdrawn
TerbutalineTerbutaline may increase the QTc-prolonging activities of Disopyramide.Approved
TertatololDisopyramide may increase the bradycardic activities of Tertatolol.Experimental
TestosteroneTestosterone may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
TetrabenazineDisopyramide may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThioridazineDisopyramide may increase the QTc-prolonging activities of Thioridazine.Approved, Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Disopyramide.Approved
TiclopidineThe metabolism of Disopyramide can be decreased when combined with Ticlopidine.Approved
TimololDisopyramide may increase the bradycardic activities of Timolol.Approved
TizanidineTizanidine may increase the QTc-prolonging activities of Disopyramide.Approved
TocilizumabThe serum concentration of Disopyramide can be decreased when it is combined with Tocilizumab.Approved
TolazamideDisopyramide may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideDisopyramide may increase the hypoglycemic activities of Tolbutamide.Approved
ToloxatoneToloxatone may increase the hypoglycemic activities of Disopyramide.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
ToremifeneDisopyramide may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Disopyramide.Experimental
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Disopyramide.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Disopyramide.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Disopyramide.Approved, Vet Approved
TroglitazoneTroglitazone may increase the hypoglycemic activities of Disopyramide.Investigational, Withdrawn
TrovafloxacinTrovafloxacin may increase the hypoglycemic activities of Disopyramide.Approved, Investigational, Withdrawn
TylosinTylosin may increase the QTc-prolonging activities of Disopyramide.Vet Approved
VandetanibDisopyramide may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Disopyramide.Approved
VemurafenibDisopyramide may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Disopyramide.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Disopyramide.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Disopyramide.Approved
VildagliptinVildagliptin may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
VogliboseVoglibose may increase the hypoglycemic activities of Disopyramide.Approved, Investigational
VoriconazoleThe metabolism of Disopyramide can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Disopyramide.Approved, Investigational
ZimelidineZimelidine may increase the hypoglycemic activities of Disopyramide.Withdrawn
ZiprasidoneThe metabolism of Disopyramide can be decreased when combined with Ziprasidone.Approved
ZuclopenthixolDisopyramide may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.

References

Synthesis Reference

Cusic, J.W. and Sause, H.W.; U.S. Patent 3,225,054; December 21,1965; assigned to G.D. Searle & Co.

US3225054
General References
Not Available
External Links
Human Metabolome Database
HMDB14425
KEGG Drug
D00303
KEGG Compound
C06965
PubChem Compound
3114
PubChem Substance
46508226
ChemSpider
3002
BindingDB
50028893
ChEBI
4657
ChEMBL
CHEMBL517
Therapeutic Targets Database
DAP000504
PharmGKB
PA449373
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Disopyramide
ATC Codes
C01BA03 — Disopyramide
AHFS Codes
  • 24:04.04.04 — Class IA Antiarrythmics

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentArrythmias / Cardiovascular Disease (CVD) / Heart Diseases / Nonvalvular Atrial Fibrillation1
3TerminatedTreatmentHeart Failure, Unspecified / Nonvalvular Atrial Fibrillation1
Not AvailableActive Not RecruitingTreatmentNonvalvular Atrial Fibrillation / Quality of Life1

Pharmacoeconomics

Manufacturers
  • Kv pharmaceutical co
  • Gd searle llc
  • Interpharm inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Superpharm corp
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral100 mg/1
CapsuleOral150 mg/1
Capsule, gelatin coatedOral100 mg/1
Capsule, gelatin coatedOral150 mg/1
CapsuleOral150 mg
Capsule, extended releaseOral100 mg/1
Capsule, extended releaseOral150 mg/1
Tablet, extended releaseOral150 mg
CapsuleOral100 mg
Tablet, extended releaseOral250 mg
Prices
Unit descriptionCostUnit
Norpace CR 150 mg 12 Hour Capsule2.35USD capsule
Norpace cr 150 mg capsule2.26USD capsule
Norpace CR 100 mg 12 Hour Capsule1.98USD capsule
Norpace 150 mg capsule1.94USD capsule
Norpace cr 100 mg capsule1.91USD capsule
Norpace 100 mg capsule1.62USD capsule
Disopyramide Phosphate 150 mg capsule0.96USD capsule
Disopyramide 150 mg capsule0.82USD capsule
Disopyramide Phosphate 100 mg capsule0.72USD capsule
Disopyramide 100 mg capsule0.69USD capsule
Rythmodan 150 mg Capsule0.43USD capsule
Rythmodan 100 mg Capsule0.3USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)94.5-95 °CCusic, J.W. and Sause, H.W.; U.S. Patent 3,225,054; December 21,1965; assigned to G.D. Searle & Co.
water solubility44.9 mg/LNot Available
logP2.58MANNHOLD,R ET AL. (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.0493 mg/mLALOGPS
logP3.21ALOGPS
logP3.47ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)16.19ChemAxon
pKa (Strongest Basic)10.42ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area59.22 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity102.3 m3·mol-1ChemAxon
Polarizability38.82 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9529
Blood Brain Barrier+0.9508
Caco-2 permeable+0.557
P-glycoprotein substrateSubstrate0.5492
P-glycoprotein inhibitor INon-inhibitor0.8677
P-glycoprotein inhibitor IINon-inhibitor0.8535
Renal organic cation transporterInhibitor0.5702
CYP450 2C9 substrateNon-substrate0.7975
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6906
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8236
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8626
Ames testNon AMES toxic0.8258
CarcinogenicityNon-carcinogens0.8873
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9764 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.996
hERG inhibition (predictor II)Inhibitor0.6168
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0005-2920000000-e596d22799910844ad71

Taxonomy

Description
This compound belongs to the class of organic compounds known as pheniramines. These are compounds containing a pheniramine moiety, which is structurally characterized by the presence of a 2-benzylpyridine linked to an dimethyl(propyl)amine to form a dimethyl[3-phenyl-3-(pyridin-2-yl)propyl]amine skeleton.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Pheniramines
Direct Parent
Pheniramines
Alternative Parents
Aralkylamines / Benzene and substituted derivatives / Heteroaromatic compounds / Trialkylamines / Carboximidic acids / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Hydrocarbon derivatives
Substituents
Pheniramine / Aralkylamine / Monocyclic benzene moiety / Benzenoid / Heteroaromatic compound / Tertiary amine / Tertiary aliphatic amine / Carboximidic acid derivative / Carboximidic acid / Azacycle
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
tertiary amino compound, monocarboxylic acid amide, pyridines (CHEBI:4657)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the pr...
Gene Name
SCN5A
Uniprot ID
Q14524
Uniprot Name
Sodium channel protein type 5 subunit alpha
Molecular Weight
226937.475 Da
References
  1. Sugao M, Fujiki A, Nishida K, Sakabe M, Tsuneda T, Iwamoto J, Mizumaki K, Inoue H: Repolarization dynamics in patients with idiopathic ventricular fibrillation: pharmacological therapy with bepridil and disopyramide. J Cardiovasc Pharmacol. 2005 Jun;45(6):545-9. [PubMed:15897781]
  2. Fujiki A, Sugao M, Nishida K, Sakabe M, Tsuneda T, Mizumaki K, Inoue H: Repolarization abnormality in idiopathic ventricular fibrillation: assessment using 24-hour QT-RR and QaT-RR relationships. J Cardiovasc Electrophysiol. 2004 Jan;15(1):59-63. [PubMed:15028073]
  3. Shimizu W, Antzelevitch C, Suyama K, Kurita T, Taguchi A, Aihara N, Takaki H, Sunagawa K, Kamakura S: Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9. [PubMed:11196553]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Yamamoto N, Ozaki T, Keida Y, Ohtsuka M, Goto T: A comparison of the binding characteristics of class I antiarrhythmic agents for human muscarinic m1-m3 receptors. J Cardiovasc Pharmacol. 1999 Jul;34(1):53-9. [PubMed:10413067]
  2. Ishida Y, Mizukami M, Taniguchi T, Satake N, Fujiwara M, Shibata S: Anticholinergic action of disopyramide in intestinal smooth muscle of the guinea pig: inhibition of muscarinic receptors (M1 and M2). Jpn J Pharmacol. 1990 Feb;52(2):363-70. [PubMed:1690310]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Yamamoto N, Ozaki T, Keida Y, Ohtsuka M, Goto T: A comparison of the binding characteristics of class I antiarrhythmic agents for human muscarinic m1-m3 receptors. J Cardiovasc Pharmacol. 1999 Jul;34(1):53-9. [PubMed:10413067]
  2. Ishida Y, Mizukami M, Taniguchi T, Satake N, Fujiwara M, Shibata S: Anticholinergic action of disopyramide in intestinal smooth muscle of the guinea pig: inhibition of muscarinic receptors (M1 and M2). Jpn J Pharmacol. 1990 Feb;52(2):363-70. [PubMed:1690310]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Yamamoto N, Ozaki T, Keida Y, Ohtsuka M, Goto T: A comparison of the binding characteristics of class I antiarrhythmic agents for human muscarinic m1-m3 receptors. J Cardiovasc Pharmacol. 1999 Jul;34(1):53-9. [PubMed:10413067]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity
Specific Function
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain. Mediates the major part of the dendritic A-type current I(SA) in brai...
Gene Name
KCND2
Uniprot ID
Q9NZV8
Uniprot Name
Potassium voltage-gated channel subfamily D member 2
Molecular Weight
70535.825 Da
References
  1. Casis O, Sanchez-Chapula JA: Disopyramide, imipramine, and amitriptyline bind to a common site on the transient outward K+ channel. J Cardiovasc Pharmacol. 1998 Oct;32(4):521-6. [PubMed:9781919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Pore-forming (alpha) subunit of voltage-gated rapidly inactivating A-type potassium channels. May contribute to I(To) current in heart and I(Sa) current in neurons. Channel properties are modulated...
Gene Name
KCND3
Uniprot ID
Q9UK17
Uniprot Name
Potassium voltage-gated channel subfamily D member 3
Molecular Weight
73450.53 Da
References
  1. Casis O, Sanchez-Chapula JA: Disopyramide, imipramine, and amitriptyline bind to a common site on the transient outward K+ channel. J Cardiovasc Pharmacol. 1998 Oct;32(4):521-6. [PubMed:9781919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Chiu PJ, Marcoe KF, Bounds SE, Lin CH, Feng JJ, Lin A, Cheng FC, Crumb WJ, Mitchell R: Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels. J Pharmacol Sci. 2004 Jul;95(3):311-9. [PubMed:15272206]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various hydrophobic ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and ava...
Gene Name
ORM2
Uniprot ID
P19652
Uniprot Name
Alpha-1-acid glycoprotein 2
Molecular Weight
23602.43 Da
References
  1. Herve F, Duche JC, d'Athis P, Marche C, Barre J, Tillement JP: Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics. 1996 Oct;6(5):403-15. [PubMed:8946472]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Echizen H, Tanizaki M, Tatsuno J, Chiba K, Berwick T, Tani M, Gonzalez FJ, Ishizaki T: Identification of CYP3A4 as the enzyme involved in the mono-N-dealkylation of disopyramide enantiomers in humans. Drug Metab Dispos. 2000 Aug;28(8):937-44. [PubMed:10901704]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Zhang L, Fitzloff JF, Engel LC, Cook CS: Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide. Xenobiotica. 2001 Feb;31(2):73-83. [PubMed:11407536]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Other/unknown
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Chu JS, Kishion S, Nomura A, Miyazaki K: Serum alpha 1-acid glycoprotein, sialic acid, and protein binding of disopyramide in normal subjects and cardiac patients. Zhongguo Yao Li Xue Bao. 1997 Sep;18(5):408-10. [PubMed:10322928]
  2. Hanada K, Ohta T, Hirai M, Arai M, Ogata H: Enantioselective binding of propranolol, disopyramide, and verapamil to human alpha(1)-acid glycoprotein. J Pharm Sci. 2000 Jun;89(6):751-7. [PubMed:10824133]
  3. Nakagawa T, Kishino S, Itoh S, Sugawara M, Miyazaki K: Differential binding of disopyramide and warfarin enantiomers to human alpha(1)-acid glycoprotein variants. Br J Clin Pharmacol. 2003 Dec;56(6):664-9. [PubMed:14616427]
  4. Haughey DB, Steinberg I, Lee MH: Protein binding of disopyramide--displacement by mono-N-dealkyldisopyramide and variation with source of alpha-1-acid glycoprotein. J Pharm Pharmacol. 1985 Apr;37(4):285-8. [PubMed:2860235]
  5. Brunner F, Muller WE: Prazosin binding to human alpha 1-acid glycoprotein (orosomucoid), human serum albumin, and human serum. Further characterization of the 'single drug binding site' of orosomucoid. J Pharm Pharmacol. 1985 May;37(5):305-9. [PubMed:2862237]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Secondary active organic cation transmembrane transporter activity
Specific Function
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
Gene Name
SLC22A1
Uniprot ID
O15245
Uniprot Name
Solute carrier family 22 member 1
Molecular Weight
61153.345 Da
References
  1. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880]
  2. Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H, Inui K: Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res. 2001 Nov;18(11):1528-34. [PubMed:11758759]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Urakami Y, Okuda M, Masuda S, Akazawa M, Saito H, Inui K: Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules. Pharm Res. 2001 Nov;18(11):1528-34. [PubMed:11758759]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2017 21:49